Table 3 The correlation of mutations in Immunodominant epitopes and C-terminal domain of HBV core protein with clinical finding of 29 chronic hepatitis B patients
From: The role of mutations in core protein of hepatitis B virus in liver fibrosis
Immunodominant epitopes Wild type/Mutant** | Wild type/Mutant** | |||||||
|---|---|---|---|---|---|---|---|---|
Mutation site | B cell | P* | CTL | P* | T helper | P* | C-terminal domain | P* |
Frequency (%) | 20/9 (68/32) | 24/5 (82/17) | 16/13 (55/45) | 24/5 (82/17) | ||||
Age (Years) | 42 ± 8/40 ± 9.6 | 0.5 | 42 ± 8.3/38 ± 9.3 | 0.3 | 42 ± 8.7/41 ± 8.5 | 0.5 | 41 ± 8/44 ± 10 | 0.6 |
ALT (IU/l) | 42 ± 18/38 ± 11 | 0.4 | 39 ± 14/48 ± 21 | 0.4 | 35 ± 13/47 ± 17 | 0.06 | 36 ± 12/62 ± 17 | 0.02 |
HBV DNA (Log copies/ml) | 4.2 ± 0.7/4.2 ± 1 | 0.9 | 4.1 ± 0.8/4.9 ± 0.7 | 0.05 | 4.3 ± 0.9/4.2 ± 0.7 | 0.6 | 4.2 ± 0.9/4.5 ± 0.3 | 0.2 |
HAI score | 6 ± 2.4/5.2 ± 2.4 | 0.4 | 5.4 ± 2.3/7.4 ± 2.1 | 0.1 | 5.6 ± 2/5.8 ± 2.8 | 0.6 | 5.3 ± 2.2/7.6 ± 2.2 | 0.06 |
Stage of Fibrosis | 1.7 ± 1.3/1.4 ± 1 | 0.4 | 1.3 ± 1/2.8 ± 1.4 | 0.3 | 1.3 ± 0.9/1.9 ± 1.5 | 0.2 | 1.3 ± 0.7/3.4 ± 1.1 | 0.02 |